



Application of Tumor mutant gene-related peptides in tumor risk intervention

Zhangjiren

Zhuijiang hospital of southern medical university

Abstract:

Cancer is caused by genetic mutations, including point mutations, deletions, insertions of gene bases, abnormal amplification of genes, and abnormal fusion of genes. Gene mutations are much earlier than clinical manifestations and can be used as markers for early diagnosis of cancer. Most patients with cancer begin to develop cancer before they have clinical symptoms. If we start with somatic mutations, the patient has developed clinical symptoms.



Biography:

Zhang Jiren is Chief Scientist & Technology Officer at Te-Pemic Health Industry Group and Technical Director for Merion, Inc. Dr. Jiren is also Member of Chinese Society of Biotechnology, Member of NEW Academy of Science & Art, Member of American College of Nutrition and Member of American Association for Cancer Research.

Publications:

Zhang Jiren, Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer

[International conference on vaccine and Vaccine Research, October 12-13, 2020, Manila, Philippines](#)

Abstract Citation: [Zhangjiren, Study on human mutant gene-related peptides in tumor risk intervention, vaccination-2020, October 12-13, 2020, Manila, Philippines](#)